Homepage Main Banner

A RADICAL NEW WAY TO TREAT SOLID TUMORS

Powerful & precise T cell therapy that attacks
solid tumors while sparing normal cells

Innovating new treatments for solid tumors

A2 Bio proprietary Tmod™ platform has the ability to absolutely distinguish tumor from normal cells

This is accomplished by integrating multiple signals, overcoming the limits of conventional single-target therapies and by exploiting common, specific gene losses only found in tumor cells

Addressing the fundamental challenge that limits the effectiveness of solid tumor treatment: absolutely distinguishing between tumor and normal cells

Novel.
Precise.
Disruptive.

OUR SCIENCE

The Tmod™ precision-targeting cell therapy platform aims the powerful armaments of immune cells at tumors, while protecting normal cells. A2 Bio has a first-mover advantage in exploiting the loss of genetic material in cancer cells.

Modular.
Flexible.
Expansive.

OUR PIPELINE

Modular and flexible, our platform is designed to enable a broad pipeline of both autologous and allogeneic cell products that access a large array of unexploited therapeutic targets, including targets previously constrained by toxicity.

Pioneering.
Experienced.
Focused.

OUR TEAM

Led by a management team with over 90 years of combined experience in cell therapy and biotechnology, A2 Bio is guided by our science and relentless focus to bring forward bold solutions that alter the course of cancer treatment.

The future of solid tumor therapy utilizes engineered cells to short-circuit immune controls and overpower cancer cells

Well Positioned to Deliver:

  • Novel approach that can distinguish tumor from normal cells
  • Modular platform enables extensive pipeline generation
  • In-house cGMP autologous & allogeneic manufacturing capability
A2Bio Website 2021SEPT15 V07

News & Events

January 13, 2021

Tempus Announces Companion Diagnostic Collaboration with A2 Biotherapeutics

December 23, 2020

A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers

October 6, 2020

A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of Its Potentially Transformative Selective Tumor Cell Therapeutics